Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal
Simcere Zaiming Pharmaceutical, an oncology-focused innovative drug company under Simcere Pharmaceutical (HKG: 2096), announced that...
SWX: ROP
Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential
Duality Biologics (HKG: 9606) announced that it has entered into a global collaboration and license...
Genentech Pledges USD 750 Million for Oregon Device Fill‑Finish Plant, Expanding Roche’s U.S. Manufacturing Footprint
Genentech, a wholly owned subsidiary of Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY), announced plans...
Roche’s Vabysmo Wins NMPA Approval for Retinal Diseases in China Market Expansion
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that China’s National Medical Products Administration (NMPA)...
Roche’s Susvimo Receives CHMP Recommendation for Neovascular AMD with Contivue Implant Delivery System
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that the European Medicines Agency’s Committee for...
Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) delivered robust first-half 2026 financial results on July...
Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the US Food and Drug...
Roche Secures CE Mark for Elecsys IGRA TB Test, Delivering Automated Solution for Tuberculosis Infection Detection
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that its Elecsys IGRA TB test has...
Astex Pharmaceuticals, Genentech Forge $515M Breast Cancer Small Molecule Drug Collaboration
Astex Pharmaceuticals announced an exclusive, worldwide research collaboration and license agreement with Genentech, a member...
Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the U.S. Food and Drug...
Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced the commercial launch of AXELIOS 1, its...
Roche’s Lunsumio-Polatuzumab Combination Accepted for FDA Review in Relapsed/Refractory Large B-Cell Lymphoma
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that the U.S. Food and Drug Administration...
Roche’s VENTANA PTEN Assay Receives FDA Approval as First Companion Diagnostic for AstraZeneca’s Truqap in Prostate Cancer
Roche Holding AG (SWX: ROP, OTCMKTS: RHHBY) announced that the VENTANA PTEN (SP218) RxDx Assay...
Nurix and Roche Forge $2.3 Billion Global Collaboration for BTK Degrader Bexobrutideg Across Oncology, Immunology and Neurology
Nurix Therapeutics, Inc. (NASDAQ: NRIX) and Roche (SWX: ROP, OTCMKTS: RHHBY) announced today a comprehensive...
Roche’s Oral SERD Giredestrant Receives FDA Priority Review for Early Breast Cancer Adjuvant Treatment
Roche Holding AG (SWX: ROP, OTCMKTS: RHHBY) announced that the U.S. Food and Drug Administration...
Roche Launches Liver Disease Panel – Digital Algorithms Combine Biomarker Diagnostics with CE-Certified LiverPRO to Transform Chronic Liver Disease Management
Roche Holding AG (SWX: ROP, OTCMKTS: RHHBY) announced the launch of its Liver Disease Panel,...
Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction
Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced that the U.S. Food and Drug Administration (FDA)...
Roche Secures CE Mark for Elecsys pTau217 Blood Test, First Single-Assay Alzheimer’s Diagnostic with Amyloid Pathology Detection
Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced on May 12, 2026, that it has received...
Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation
Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced a definitive agreement to acquire PathAI, a leading...
Roche Q1 Sales Rise 6% Driven by Innovative Medicines as China Expansion and Diagnostics Recovery Offset Currency Headwinds
Roche AG (SWX: ROP, OTCMKTS: RHHBY) reported first-quarter 2026 group sales of CHF 14.7 billion...